14 Results

People

  1. Giralt
    Giralt
  2. Hassoun
    Hassoun
  3. Lesokhin
    Lesokhin
  4. Mailankody
    Mailankody
  5. Shah
    Shah
  6. Chung
    Chung
  7. Hultcrantz
    Hultcrantz
  8. Korde
    Korde
  9. Landau
    Landau
  10. Scordo
    Scordo

Groups

  1. Bone Marrow Transplant (14)
  2. Center for Hematologic Malignancies (14)
  3. Department of Medicine (14)
  4. Hematologic Malignancies Research (14)
  5. Hematologic Malignancies, Division of (14)
  6. Myeloma (14)
  7. Survivorship Research (14)
  8. CTCR Scholars (13)
  9. Sloan Kettering Institute Postdocs (13)
  10. Epidemiology and Biostatistics (10)
  1. "multiple myeloma"
  2. "Hani Hassoun"
  3. "Gunjan Shah"
Formats
  1. Journal Article (11)
  2. Correspondence (1)
  3. Meeting Abstract (1)
  4. Research Letter (1)
Groups
  1. Bone Marrow Transplant (14)
  2. Center for Hematologic Malignancies (14)
  3. Department of Medicine (14)
  4. Hematologic Malignancies Research (14)
  5. Hematologic Malignancies, Division of (14)
  6. Myeloma (14)

More Groups

People
  1. Alexander Lesokhin (14)
  2. Gunjan Shah (14)
  3. Hani Hassoun (14)
  4. Sergio Giralt (14)
  5. Sham Mailankody (14)
  6. David Chung (13)

More People

Years
  1. 2023 (4)
  2. 2022 (3)
  3. 2021 (2)
  4. 2020 (3)
  5. 2019 (1)
  6. 2018 (1)
Publications
  1. Biology of Blood and Marrow Transplantation (2)
  2. Clinical Lymphoma, Myeloma and Leukemia (2)
  3. American Journal of Hematology (1)
  4. Blood Cancer Journal (1)
  5. Clinical Cancer Research (1)
  6. JAMA Oncology (1)

More Publications

Publishers
  1. Elsevier Inc. (5)
  2. Nature Publishing Group (2)
  3. American Association for Cancer Research (1)
  4. American Medical Association (1)
  5. Elsevier Science, Inc. (1)
  6. John Wiley & Sons, Inc. (1)

More Publishers

Results (14)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Journal Article

    Maura, F.; Boyle, E. M.; Coffey, D.; Maclachlan, K.; Gagler, D.; Diamond, B.; Ghamlouch, H.; Blaney, P.; Ziccheddu, B.; Cirrincione, A.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Journal Article

    Tan, C. R.; Derkach, A.; Nemirovsky, D.; Ciardiello, A.; Diamond, B.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Maclachlan, K.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save
  • Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: A prospective observational cohort study
    Journal Article

    Korde, N.; Tavitian, E.; Mastey, D.; Lengfellner, J.; Hevroni, G.; Zarski, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; more...
    eClinicalMedicine (2023)

    Fulltext@MSK | Save
  • Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach
    Journal Article

    Pianko, M. J.; Tiutan, T.; Derkach, A.; Flynn, J.; Salvatore, S. P.; Jaffer-Sathick, I.; Rossi, A. C.; Lahoud, O.; Hultcrantz, M.; Shah, U. A.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • GPRC5D-targeted CAR T cells for myeloma
    Journal Article

    Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Capture rate of V(D)J sequencing for minimal residual disease detection in multiple myeloma
    Journal Article

    Hultcrantz, M.; Rustad, E. H.; Yellapantula, V.; Jacob, A.; Akhlaghi, T.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Smith, E. L.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Stem cell mobilization and autograft minimal residual disease negativity with novel induction regimens in multiple myeloma
    Journal Article

    Bal, S.; Landau, H. J.; Shah, G. L.; Scordo, M.; Dahi, P.; Lahoud, O. B.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Lendvai, N.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save